Drug intelligence / Profile preview

Antiwei Granules

Development stage: Phase 3
Lead developer: Tasly Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

Antiwei Granules is a Traditional Chinese Medicine (TCM) product developed by Tasly Pharmaceutical Group for the treatment of the common cold, specifically targeting the wind-cold syndrome. It is a multi-ingredient herbal formulation designed to alleviate symptoms such as fever, chills, headache, and nasal congestion. The drug has undergone evaluation in multicenter, randomized, double-blind, placebo-controlled Phase III clinical trials to establish its efficacy and safety profile. As a TCM granule, it is intended for oral administration and works through the synergistic effects of its constituent herbal extracts to modulate the body's response to viral respiratory infections.

Brand names: Antiwei Granules
Other names: An Ti Wei Ke Li

Beyond the preview

Go deeper on Antiwei Granules.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Antiwei Granules.

Explore the full profile